Genomic Health (NASDAQ: GHDX) closed up 10.2% Tuesday following its announcement of solid fourth-quarter earnings after the bell Monday. The company’s 2017 guidance certainly didn’t hurt investors’ confidence either.
Image source: Getty Images.
Genomic Health delivered 8% more genetic tests in the fourth quarter than it did in Q4 2015. More importantly, product revenue rose even faster — up 10% year over year — as the company was able to get paid for more of its genetic cancer tests from insurers and government programs.